TRPS1 antisense RNA 1 (TRPS1-AS1)

**TRPS1 antisense RNA 1 (TRPS1-AS1)** is a long non-coding RNA (lncRNA) that functions as an antisense transcript overlapping the TRPS1 gene locus[4][5]. TRPS1-AS1 is significantly upregulated in paclitaxel-resistant triple-negative breast cancer (TNBC) cells; its overexpression reduces sensitivity to paclitaxel, while knockdown of TRPS1-AS1 increases sensitivity[1]. Mechanistically, TRPS1-AS1 directly binds to the TRPS1 mRNA or protein and downregulates its expression, affecting cellular response to chemotherapy[1]. Its primary function is regulatory, influencing gene expression levels and contributing to drug resistance rather than serving as a classic therapeutic target such as a receptor, enzyme, or transporter[3][4]. Key Notes: - **TRPS1-AS1 is not a classical drug target** (such as a receptor, enzyme, transporter, or ion channel)[1][4][5]. It is a regulatory RNA molecule whose functional significance is mainly in cancer cell biology and chemoresistance. - **No direct drugs or clinical biomarkers** currently target TRPS1-AS1; its principal impact is indirect, by altering sensitivity to chemotherapy (notably paclitaxel in breast cancer)[1]. - **Aliases** include AF178030.2 and TRPS1-AS1[1][4][5]. - **Molecular class** is lncRNA/antisense RNA, distinct from protein-coding gene targets like TRPS1 itself[4][5]. - **Associated disease role** is mediated via regulation of oncogenic processes and drug resistance in cancer, especially breast cancer[1][6]. If you are seeking a *therapeutic target*, TRPS1-AS1 is not a prototypical or validated drug target but is of research interest as a modulator of drug response in oncology.

Other names

AF178030.2TRPS1-AS1